New Delhi: Dr Reddys Laboratories said it has launched a generic version of Sofosbuvir 400 mg and Velpatasvir 100 mg fixed-dose combination, indicated for the treatment of chronic hepatitis C, in the country.
The Hyderabad-based firm has launched its generic product under the brand name Resof Total, Dr Reddys Laboratories said in a statement.
Dr Reddys product is a generic version of Gileads brand Epclusa.
“Treatment with this combination achieves a cure rate of more than 90 per cent in all genotypes of Hepatitis C virus,” the company said.
Shares of the company ended 3.54 per cent up at Rs 2,676.15 on BSE.
0 comment(s) on Dr Reddys Laboratories launches generic hepatitis C drug in India
